Kinnate Biopharma appoints Mark Meltz as chief operating officer and general counsel

Kinnate Biopharma, a precision oncology company focused on the discovery and development of novel kinase inhibitors, announced the appointment of Mark Meltz as chief operating officer and general counsel. Company further announced the appointment of Nima Farzan as Chief Executive Officer.

Meltz joins Kinnate from Audentes Therapeutics where he was senior vice president and general counsel and helped lead the sale of the company to Astellas Pharma in January 2020. Prior, he was executive vice president and chief business development and legal officer at PaxVax where he helped lead the sale of the company to Emergent BioSolutions, served as associate general counsel at Biogen and was head of legal for North America at Novartis in its Vaccines & Diagnostics division.